Sagimet Biosciences (SGMT) Financials

Sagimet Biosciences (NASDAQ: SGMT) remains a pre-revenue biotech with a very strong cash position, but its quarterly losses are still significant and ongoing. The latest Q1 2026 results show no revenue, continued heavy spending on research and development, and another quarterly net loss. At the same time, the company still holds more than $100 million in cash and investments, which gives it flexibility to keep funding its pipeline.

• Strong liquidity cushion: As of Q1 2026, SGMT reported about $36.6 million in cash and $67.9 million in short-term investments, for roughly $104.5 million in liquid assets.
• No financing needed in the latest quarter: SGMT reported zero financing cash flow in Q1 2026, suggesting it did not need to raise capital during the quarter.
• Cash balance improved sequentially: Cash and equivalents rose from $32.5 million in Q3 2025 to $36.6 million in Q1 2026.
• Other income helps offset burn: Interest and investment income contributed $1.1 million in Q1 2026, which partially softened operating losses.
• Large investment portfolio provides flexibility: The company continues to hold a meaningful amount of its balance sheet in marketable investments, which can support operations if needed.
• Balance sheet still shows high equity: Total common equity was $102.5 million at the end of Q1 2026, though this is largely accounting-driven and not a sign of profitability.
• Operating cash burn remains material: SGMT used $8.6 million in operating cash during Q1 2026, which is a manageable burn rate for now but still meaningful over time.
• No revenue yet: SGMT reported $0 in revenue in Q1 2026, and the company has also shown no revenue in recent prior quarters. That means the business is still fully dependent on its clinical and development pipeline.
• Ongoing quarterly losses: SGMT posted a $10.7 million net loss in Q1 2026, slightly worse than the $9.6 million loss in Q4 2025.
• R&D spending remains elevated: Research and development expense was $7.0 million in Q1 2026, after $6.7 million in Q4 2025, reflecting continued cash burn to advance the pipeline.
• Prior-year cash runway has declined: Cash and equivalents plus investments were much higher in early 2024, so the company has been using its balance sheet to fund ongoing operations.

Bottom line: Sagimet Biosciences looks well-capitalized for a biotech with no revenue, but investors should expect continued losses and cash usage until one of its programs creates a meaningful commercial or clinical catalyst. The key question is not current profitability, but whether the company can convert its cash runway into pipeline success before needing to raise more capital.